Real-world brivaracetam shows durable retention and early patient-reported benefits in difficult-to-control focal seizures
A 12-month US prospective observational study found brivaracetam retention at 12 months of 57% (intent-to-treat) and 72% among those with known treatment status, early improvement in seizure-related disability and PROMIS domains, and a safety profile consistent with prior experience.